Delivery Order 75F40118D10053-75F40119F19002

Award Date 9/27/19
Potential Completion Date 9/26/20
Potential Value $7.1M
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Time and Materials
Place of Performance
Westlake, MD 20817, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
3
Legislative Mandate
Service Contract Act
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Department of Health and Human Services Food and Drug Administration awarded a $14,609,200.89 delivery order contract to International Business Machines Corporation (IBM) for the "DEVELOPMENT OF NEW AND INNOVATIVE METHODS FOR AUTOMATED REPORTING FOR CBER-REGULATED BIOLOGICAL PRODUCTS". This contract is a Time and Materials type under the BEST Initiative - New and Innovative Methods for Automated Reporting master IDIQ. The contract does not have a set-aside designation. IBM, as...
This federal contract award was issued by the Food and Drug Administration (FDA) to International Business Machines Corporation (IBM) to support the Center for Biologics Evaluation and Research (CBER) Biologics Effectiveness and Safety (BEST) Initiative. The $8,234,421.12 delivery order contract will develop new and innovative methods for automated reporting for CBER-regulated biologics. The contract is a Time and Materials (T&M) type and does not have a set-aside designation. IBM will be...
This is a delivery order contract awarded by the Department of Health and Human Services Food and Drug Administration (FDA) to International Business Machines Corporation (IBM) for the development of new and innovative methods for automated reporting for biological products regulated by the FDA's Center for Biologics Evaluation and Research (CBER). The contract has a potential value of $6,999,176.74 and is on a time and materials pricing basis. It was awarded under the BEST Initiative master...
This federal contract was awarded by the Department of Health and Human Services Food and Drug Administration to the International Business Machines Corporation (IBM) on September 24, 2019. The $5,622,942.08 time and materials contract is a delivery order under the BEST Initiative - Data Tools and Infrastructure for Surveillance of Biologics master IDIQ contract vehicle. The objective is for IBM to conduct surveillance activities to assess the safety and effectiveness of biologics. This work...
The Department of Health and Human Services Food and Drug Administration (HHS FDA) awarded a $13.2 million delivery order contract to International Business Machines Corporation (IBM) under the Biologics Effectiveness and Safety (BEST) Initiative - Data Tools and Infrastructure for Surveillance of Biologics indefinite-delivery/indefinite-quantity (IDIQ) contract vehicle. The contract calls for IBM to provide data, tools, and infrastructure to support HHS FDA's BEST Initiative for surveillance of...
The Department of Health and Human Services Food and Drug Administration awarded a $2,611,999.89 Delivery Order contract to International Business Machines Corporation (IBM) on June 19, 2018 for CDER Business Informatics Governance & Process Implementation services. This contract, which did not have a set-aside designation, had a completion date of September 30, 2019. As a major federal IT services provider, IBM has supported various government agencies through prime and subcontract awards...
This is a $483,230.06 delivery order contract awarded by the Department of Health and Human Services Food and Drug Administration (FDA) to International Business Machines Corporation (IBM) for testing data standards support. The contract does not have a set-aside designation. IBM is a major information technology services provider to the federal government, supporting critical systems and operations across civilian and defense agencies. This delivery order contract is likely part of a larger...
This is a $636,006.69 delivery order contract awarded by the Food and Drug Administration (FDA) to International Business Machines Corporation (IBM) on August 17, 2015. The contract is for labor hours pricing and has an ultimate completion date of December 31, 2016. The contract is not set aside. IBM, the prime contractor, is a major global technology company that provides a wide range of hardware, software, cloud computing, artificial intelligence, and consulting services to the U.S. federal...
The Department of Health and Human Services (HHS) Food and Drug Administration (FDA) awarded a $1,636,498.43 firm fixed price delivery order to International Business Machines Corporation (IBM) for data management support services. The order was not set aside for any specific business size or type. IBM is a major IT services provider that supports federal agencies through prime contracts and subcontracts, including work for the General Services Administration, Federal Emergency Management...
This is a $639,252.05 delivery order awarded by the Department of Health and Human Services Food and Drug Administration to International Business Machines Corporation (IBM) on August 23, 2018. The contract is for testing data standards and enhancing testing standard operating procedures. It has a completion date of September 16, 2019 and uses a labor hours pricing type. The contract does not have a set-aside designation. IBM is a major federal information technology contractor that provides...

International Business Machines Corporation (IBM) was awarded a $7,081,492.15 delivery order against the Center for Biologics Evaluation and Research (CBER) Biologics Effectiveness and Safety (BEST) Initiative master indefinite delivery/indefinite quantity contract by the Department of Health and Human Services Food and Drug Administration. The delivery order is for the development of new and innovative methods for automated reporting to support CBER-regulated biologics and has a completion date of September 26, 2020. There is no set-aside designation. IBM will leverage its expertise in information technology and consulting to assist the FDA's CBER division, which regulates cell and gene therapies, blood, vaccines, and other biologics, in modernizing its reporting processes through September 2020.

Generated 2/24/24, 9:54 AM